European Psychiatry - Volume 33 - March 2016

679 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S675
From a sample of 51 inpatients, 15 of them were diagnosed with
disorders of the spectrumof schizophrenia and other psychotic dis-
orders. Of the patients, 13.3% was treated with haloperidol, 26.7%
with olanzapine, 26.7% with risperidone although it was modi-
fied by paliperidone in mental health center, 6.7% with quetiapine,
6.7% with amisulpride, 13.3% with oral paliperidone and 13.3%
patients with intramuscular paliperidone. Of these, 40% are read-
mitted to hospital. Patients were readmitted due to ineffectiveness
and adverse effects of haloperidol, olanzapine, risperidone. 73.3% of
inpatients were treated with monotherapy. Of the patients, 26.7%
were treated with polytherapy, who received olanzapine, risperi-
done and amisulpride. It would be important to use psychoactive
substances that allow monotherapy to reduce adverse effects and
psychiatric re-hospitalization.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1019
Effects of using psychotropic drugs in
the etiology and prevention of deviant
behavior
S. Ibrahimi
Albanian University, Psychology, Tirana, Albania
Objective The objective of the article is to explore the main fea-
tures of the relationship between these components that produce
the effect in the etiology of deviant behavior.
Methods The study is a comprehensive and comparative of data
in the pharmaco-epidemology groups of Mental Health Care and
Community Centers in Albania in 2014–2015. The methods used
are explorative, qualitative and epidemiologic as to the reports of
subjects and official data.
Results The psychiatry of changing behavior is certainly a mile-
stone of the nowadays health. Data collected from a 6-month
follow-up of new cases of youth with an uncontrolled impulse and
a low ego resilience on a psychotropic prescription have given a
clear view of connection between the type of psychotropic drug
used and the level of reaction the drug has created in the prevention
of a further development of deviant behavior.
Conclusions In the end of this approach, we could reach to con-
firm that the more the knowledge on the usage and effects of
psychotropic drugs, the better will be the preventive efforts to their
effects over the deviant behavior in the individual.
Keywords Psychotropic; Deviant behavior; Ethiology;
Prevention; Adverse effect
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EV1020
New models for research and
development in the treatment of
mental illness
J.N. Kjær
Aarhus University Hospital, 1 Department of Organic Psychiatric
Disorders and Emergency Ward, Risskov, Denmark
The pharmaceutical industry’s investments in research and devel-
opment of novel treatments for mental illness have heavily
declined in the past decade. Major private investments are, by
most experts, seen as necessary to develop new treatments. How-
ever, psychiatry is not the only area overlooked by the industry.
For decades infectious diseases have also lacked investments in
research and development.
Aims The aims of this study were to investigate the new models
of research and development in infectious diseases that emerged
after the pharmaceutical industry ceased their investments and to
model how these can be used in psychiatry.
Method A systematic review. We searched PubMed, EMBASE and
Web of Science for the keywords “infectious diseases”, “research
and development” and “pharmaceutical industry”.
Preliminary results The searches gave a total of 248 references.
Among the findings, we want to highlight the Drugs for Neglected
Diseases initiative (DNDi) and the WHO Research and Develop-
ment Treaty (R&D Treaty). DNDi is a non-profit organization that
has developed six new drugs since 2003. The development costs
wereD 150 millions per drug, which is considerably belowthe costs
for drug development claimed by the pharmaceutical industry. The
R&D Treaty will commit member states of the WHO to fund devel-
opment for neglected health needs using alternative incentives like
milestone prizes, patent pools and direct grants. The treaty has not
yet been agreed upon.
Conclusions Though a low priority from the pharmaceutical
industry, other funding models have proven able to deliver new
treatments. This could also lead to more development of non-
patentable treatments, e.g. psychotherapy.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EV1021
Clinical and socio-demographic
characteristics of a sample of
outpatients with long-acting
injectable antipsychotic treatment
J. Moreno Monmany∗, I. Tinoco Calero , N. Bagué Gomez ,
B. Samsó Buxareu , V. Chavarria Romero , S. Castillo Maga˜na ,
S. Oller Canet
Parc de Salut Mar, INAD, Barcelona, Spain
∗ Corresponding author.
Introduction There are relatively few studies of Long-acting
injectable antipsychotics (LAI), although poor adherence to treat-
ment is one of the main problems in patients with psychotic
disorders.
Objectives The aim of the study is to describe socio-demographic
and clinical characteristics of a sample of outpatientswith LAI treat-
ment.
Methods This is a cross-sectional study. A randomized sam-
pling was performed among the outpatients that were receiving
LAI in an outpatient clinic in Barcelona (Spain). For each patient,
socio-demographic, clinical and pharmacotherapeutic data were
collected through interviews and clinical history.
Results The sample consisted of 30 subjects (50% men, average
age 48 years). Most of the patients in the sample have basic edu-
cation (50%) and are unemployed, receiving permanent disability
pension (39.3%). In addition, 44.8% of the subjects were living with
family members and were not married (56.7%). Of the patients,
70%were diagnosed with schizophrenia, 13.3% schizoaffective, 10%
bipolar and 6.7% delusional disorder. Themain reason to initiate LAI
treatment was due to non-compliance of the prescribed oral treat-
ment (85.7%). The 40% of patients were also with oral antipsychotic
treatment. Average punctuation in the 3 first items of the Scale to
Assess Unawareness of Mental Disorder: 11. Average punctuation
in the short version of the Simpson-Angus Scale: 1.68.
Conclusions In our sample, the outpatients with LAI treatment
had a low functioning and disease awareness. Although the main
reason to start LAI is the non-compliance, 40% of the patients were
concurrently treated with oral antipsychotics. The extrapyramidal
side effects are mild.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.